

Cyclacel Pharmaceuticals develops oral therapies to treat cancers and other critical diseases. Among its major competitors, Cyclacel Pharmaceuticals is ranked in 5th place for NPS while Bristol Myers Squibb is 1st, and GlaxoSmithKline is 2nd.Their current market cap is $8.28M